-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Rotaviruses -X- _ B-Patient
are -X- _ O
the -X- _ O
single -X- _ O
most -X- _ O
important -X- _ O
cause -X- _ O
of -X- _ O
severe -X- _ O
diarrhea -X- _ O
in -X- _ O
young -X- _ O
children -X- _ O
worldwide. -X- _ O
The -X- _ O
developments -X- _ O
of -X- _ O
specific -X- _ O
, -X- _ O
potent -X- _ O
and -X- _ O
accessible -X- _ O
antiviral -X- _ O
treatments -X- _ O
that -X- _ O
restrain -X- _ O
rotavirus -X- _ O
infection -X- _ O
remain -X- _ O
important -X- _ O
to -X- _ O
control -X- _ O
rotavirus -X- _ B-Patient
disease. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
150 -X- _ B-Intervention
plant -X- _ I-Intervention
extracts -X- _ I-Intervention
with -X- _ O
nutritional -X- _ O
applications -X- _ O
were -X- _ O
screened -X- _ O
in -X- _ O
vitro -X- _ O
on -X- _ O
MA-104 -X- _ B-Patient
cells -X- _ I-Patient
for -X- _ O
their -X- _ O
antiviral -X- _ O
activity -X- _ O
against -X- _ O
rhesus -X- _ O
rotavirus -X- _ O
( -X- _ O
RRV -X- _ O
) -X- _ O
. -X- _ O
One -X- _ O
extract -X- _ O
( -X- _ O
Aspalathus -X- _ B-Intervention
linearis -X- _ I-Intervention
( -X- _ I-Intervention
Burm.f. -X- _ I-Intervention
) -X- _ I-Intervention
R.Dahlgren -X- _ I-Intervention
) -X- _ O
was -X- _ O
also -X- _ O
tested -X- _ O
for -X- _ O
its -X- _ O
effect -X- _ O
on -X- _ O
the -X- _ O
loss -X- _ O
of -X- _ O
transepithelial -X- _ O
resistance -X- _ O
( -X- _ O
TER -X- _ O
) -X- _ O
of -X- _ O
Caco-2 -X- _ O
cells -X- _ O
caused -X- _ O
by -X- _ O
simian -X- _ O
rotavirus -X- _ O
( -X- _ O
SA-11 -X- _ O
) -X- _ O
infection. -X- _ O
RESULTS -X- _ O
: -X- _ O
Aqueous -X- _ B-Outcome
extracts -X- _ I-Outcome
of -X- _ I-Outcome
Nelumbo -X- _ I-Outcome
nucifera -X- _ I-Outcome
Gaertn. -X- _ I-Outcome
fruit -X- _ I-Outcome
, -X- _ I-Outcome
Urtica -X- _ I-Outcome
dioica -X- _ I-Outcome
L. -X- _ I-Outcome
root -X- _ I-Outcome
, -X- _ I-Outcome
Aspalathus -X- _ I-Outcome
linearis -X- _ I-Outcome
( -X- _ I-Outcome
Burm.f. -X- _ I-Outcome
) -X- _ I-Outcome
R.Dahlgren -X- _ I-Outcome
leaves -X- _ I-Outcome
, -X- _ I-Outcome
Glycyrrhiza -X- _ I-Outcome
glabra -X- _ I-Outcome
L. -X- _ I-Outcome
root -X- _ I-Outcome
and -X- _ I-Outcome
Olea -X- _ I-Outcome
europaea -X- _ I-Outcome
L. -X- _ I-Outcome
leaves -X- _ I-Outcome
were -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
have -X- _ I-Outcome
strong -X- _ I-Outcome
significant -X- _ I-Outcome
antiviral -X- _ I-Outcome
activity -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
inhibitory -X- _ I-Outcome
concentration -X- _ I-Outcome
( -X- _ I-Outcome
IC50 -X- _ I-Outcome
) -X- _ I-Outcome
< -X- _ I-Outcome
300 -X- _ I-Outcome
μg -X- _ I-Outcome
/ -X- _ I-Outcome
ml. -X- _ I-Outcome
The -X- _ O
pure -X- _ B-Outcome
compound -X- _ I-Outcome
18ß-glycyrrhetinic -X- _ I-Outcome
acid -X- _ I-Outcome
from -X- _ I-Outcome
Glycyrrhiza -X- _ I-Outcome
glabra -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
have -X- _ I-Outcome
the -X- _ I-Outcome
strongest -X- _ I-Outcome
antiviral -X- _ I-Outcome
activity -X- _ I-Outcome
( -X- _ I-Outcome
IC50 -X- _ I-Outcome
46 -X- _ I-Outcome
μM -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
followed -X- _ I-Outcome
by -X- _ I-Outcome
luteolin -X- _ I-Outcome
and -X- _ I-Outcome
vitexin -X- _ I-Outcome
from -X- _ I-Outcome
Aspalathus -X- _ I-Outcome
linearis -X- _ I-Outcome
( -X- _ I-Outcome
IC50 -X- _ I-Outcome
respectively -X- _ I-Outcome
116 -X- _ I-Outcome
μM -X- _ I-Outcome
and -X- _ I-Outcome
129 -X- _ I-Outcome
μM -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
apigenin-7-O-glucoside -X- _ I-Outcome
from -X- _ I-Outcome
Melissa -X- _ I-Outcome
officinalis -X- _ I-Outcome
( -X- _ I-Outcome
IC50 -X- _ I-Outcome
150 -X- _ I-Outcome
μM -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
A -X- _ I-Outcome
combination -X- _ I-Outcome
of -X- _ I-Outcome
Glycyrrhiza -X- _ I-Outcome
glabra -X- _ I-Outcome
L. -X- _ I-Outcome
+ -X- _ I-Outcome
Nelumbo -X- _ I-Outcome
nucifera -X- _ I-Outcome
Gaertn. -X- _ I-Outcome
and -X- _ I-Outcome
Urtica -X- _ I-Outcome
dioica -X- _ I-Outcome
L. -X- _ I-Outcome
+ -X- _ I-Outcome
Nelumbo -X- _ I-Outcome
nucifera -X- _ I-Outcome
Gaertn. -X- _ I-Outcome
showed -X- _ I-Outcome
synergy -X- _ I-Outcome
in -X- _ I-Outcome
their -X- _ I-Outcome
anti-viral -X- _ I-Outcome
activities. -X- _ I-Outcome
Aspalathus -X- _ I-Outcome
linearis -X- _ I-Outcome
( -X- _ I-Outcome
Burm.f. -X- _ I-Outcome
) -X- _ I-Outcome
R.Dahlgren -X- _ I-Outcome
showed -X- _ I-Outcome
no -X- _ I-Outcome
positive -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
maintenance -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
TER. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
These -X- _ O
results -X- _ O
indicate -X- _ O
that -X- _ O
nutritional -X- _ O
intervention -X- _ O
with -X- _ O
extracts -X- _ O
of -X- _ O
Nelumbo -X- _ B-Outcome
nucifera -X- _ I-Outcome
Gaertn. -X- _ I-Outcome
, -X- _ I-Outcome
Aspalathus -X- _ I-Outcome
linearis -X- _ I-Outcome
( -X- _ I-Outcome
Burm.f. -X- _ I-Outcome
) -X- _ I-Outcome
R.Dahlgren -X- _ I-Outcome
, -X- _ I-Outcome
Urtica -X- _ I-Outcome
dioica -X- _ I-Outcome
L. -X- _ I-Outcome
, -X- _ I-Outcome
Glycyrrhiza -X- _ I-Outcome
glabra -X- _ I-Outcome
L. -X- _ I-Outcome
and -X- _ I-Outcome
Olea -X- _ I-Outcome
europaea -X- _ I-Outcome
L. -X- _ I-Outcome
might -X- _ I-Outcome
be -X- _ I-Outcome
useful -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
diarrhea -X- _ I-Outcome
caused -X- _ I-Outcome
by -X- _ I-Outcome
rotavirus -X- _ I-Outcome
infection -X- _ I-Outcome
. -X- _ O

